Actively Recruiting
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2024-06-21
129
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the tolerability and safety of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC; To evaluate the efficacy of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC.
CONDITIONS
Official Title
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years, male or female
- Diagnosed with incurable advanced hepatocellular carcinoma (HCC)
- For Stage 1: failed standard treatment or unwilling to accept it
- For Stage 2: no prior immunotherapy and no more than one previous systemic treatment
- At least one measurable tumor lesion per RECIST v1.1
- Barcelona Clinic Liver Cancer stage B or C
- ECOG performance status score of 0 or 1
- Child-Pugh liver function score of 7 or less
- Expected survival of at least 3 months
- Adequate organ function
You will not qualify if you...
- Fibrolamellar hepatocellular carcinoma, sarcomatoid HCC, or mixed cholangiocarcinoma/HCC
- Active, known, or suspected autoimmune disorders
- Systemic corticosteroid or immunosuppressant treatment within 1 month before first dose
- Known severe allergic reactions to monoclonal antibodies
- Central nervous system metastasis or hepatic encephalopathy
- Liver tumor burden over 50% of total liver volume or prior liver transplantation
- Symptomatic ascites or pleural effusion requiring drainage, or drainage within 2 weeks before first dose
- Other malignancies currently or within the past 5 years
- Poorly controlled hypertension
- Uncontrolled heart diseases or symptoms
- Any other conditions that may affect study results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Provincial Hospital Ethics Commitee
Hefei, Anhui, China, 230000
Actively Recruiting
Research Team
X
Xin Shi
CONTACT
Y
Ying Sun
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here